Rapid Dose Therapeutics gains ANVISA approval to sell medical cannabis QuickStrip in Brazil

Canadian firm's oral cannabis product enters Brazilian market after regulatory clearance, following patient base growth to 873,000.

FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0

Rapid Dose Therapeutics has secured ANVISA approval to launch its QuickStrip medical cannabis product in Brazil, according to reporting from TMX Newsfile. The move marks entry into a market that has expanded significantly since Brazil authorized medical cannabis cultivation in January 2026 and now counts approximately 873,000 registered patients.

The approval arrives as Brazil's medical cannabis sector continues attracting investment and regulatory attention. Recent coverage indicates the market has drawn new capital, while authorities have simultaneously worked to control unlicensed production—the country's police destroyed 60,000 marijuana plantations in late July. The QuickStrip's oral format may appeal to patients and physicians navigating a still-evolving regulatory and supply environment.

Watch for adoption metrics and whether Rapid Dose's product gains meaningful market share against existing medical cannabis options in Brazil, where patient numbers have grown sharply. Competition and pricing relative to other approved formulations will signal the product's commercial viability.